GenoDx

Executive Summary

GenoDx is a US-based precision oncology company advancing cancer diagnostics through a platform that integrates next-generation sequencing with proprietary AI algorithms to identify actionable mutations and guide personalized treatment. Founded in 2017 and based in San Diego, the company has raised $350 million and operates at a commercial stage with 200-500 employees. GenoDx focuses on improving therapeutic outcomes by enabling earlier and more accurate detection of resistant or recurrent disease, positioning itself as a key player in the growing precision oncology market. Its technology addresses a critical need in oncology: the timely identification of biomarkers that inform targeted therapy selection and monitoring of treatment response.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of Liquid Biopsy Test for Therapy Monitoring60% success
• Q2 2026Strategic Partnership with Major Pharma for Companion Diagnostic Development55% success
• Q4 2026Launch of Expanded Panel Covering New Actionable Mutations70% success